To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Dopamine cell death attending Parkinson's disease (PD) profoundly alters the sleep-wake state which can be classified into disturbances of: nocturnal movement, and thalamocortical arousal state. Diurnal rhythms in the content, turnover, release and behavioral responsiveness of the brain's principal dopamine systems are well established. Clinicians have long relied upon the wake-promoting effects of dopaminomimetics inclusive of traditional psychostimulants. Apart from the neurobiological substrates governing PD, genetic and disease factors may also influence expression of sleepiness and sleep onset rapid-eye-movement sleep (SOREMs). The utility of the multiple sleep latency test (MSLT), and other objective and subjective measures of sleepiness in PD has been reviewed. The clinician treating sleepiness in the parkinsonian patient is in the unenviable position of weighing the potential positive impact of dopaminomimetics upon sleep as it relates to daytime motor function, against the real possibility of adverse effects upon daytime alertness.